Healthcare / BiotechnologyTaipei Exchange
$34.65
-1.05 (-2.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $24.3M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
866.3x
↑EV/EBITDA
24.2x
↑ROE
5.1%
↑Gross Margin
61.8%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+4.2%
FCF CAGR
-0.6%
FCF margin
12.0%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $202.7M · net income $22.7M · FCF $24.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $202.7M | $202.7M | $228.3M | $231.4M | $179.3M |
| Net Income | $22.7M | $22.7M | $37.7M | $61.3M | $46.3M |
| EBITDA | $46.6M | $46.6M | $65.0M | $88.9M | $57.4M |
| EPS | 0.69 | 0.69 | 1.14 | 1.84 | 1.47 |
| Gross Margin | 61.8% | 61.8% | 66.9% | 66.0% | 61.6% |
| Operating Margin | 9.5% | 9.5% | 19.5% | 28.1% | 24.8% |
| Net Margin | 11.2% | 11.2% | 16.5% | 26.5% | 25.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.22 | 0.03 | 0.02 |
| Cash Flow | |||||
| Free Cash Flow | $24.3M | $24.3M | $-126.9M | $62.6M | $24.7M |
| Returns | |||||
| ROE | 5.1% | 5.1% | 8.7% | 14.6% | 12.6% |
| Valuation | |||||
| P/E | 866.25 | 866.25 | 35.49 | 20.05 | 21.15 |
| EV/EBITDA | 24.22 | 24.22 | 20.79 | 11.65 | 14.55 |
| P/B | 2.54 | 2.54 | 3.10 | 2.94 | 2.66 |
| Growth & Yield | |||||
| Revenue Growth | -11.2% | -11.2% | -1.4% | 29.1% | — |
| EPS Growth | -39.3% | -39.3% | -38.1% | 24.7% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
64.6%
EPS terminal req.
$3.07
Spread vs growth
-103.8%
5Y implied EPS CAGR
40.1%
EPS terminal req.
$3.72
Spread vs growth
-79.4%
10Y implied EPS CAGR
24.1%
EPS terminal req.
$5.99
Spread vs growth
-63.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.8%
Start / end P/E
37.0x → 50.2x
EPS bridge
1.14 → 0.69
Residual
-14.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.